A new review of 43 clinical studies has found that marijuana and cannabinoid-based treatments can help reduce pain and improve sleep among people with rheumatic diseases, with the strongest evidence of potential benefits found in patients with fibromyalgia.
The review, published October 27 in the peer-reviewed journal Joint Bone Spine, was conducted by researchers affiliated with Cochin Hospital, Université Paris Cité and INSERM in France. It examined research published between 2000 and 2026 to evaluate the effectiveness and safety of cannabis and cannabinoids for conditions involving chronic pain, inflammation and musculoskeletal symptoms.
Researchers identified 43 clinical publications, including randomized controlled trials, observational studies and previous reviews, along with 17 preclinical studies examining how cannabinoids affect biological processes associated with rheumatic diseases.
Fibromyalgia accounted for the largest share of the clinical literature, with 28 publications, including seven randomized controlled trials, 12 other clinical studies and nine reviews. The analysis also included 10 publications examining osteoarthritis, two involving rheumatoid arthritis, and one each addressing psoriatic arthritis and systemic sclerosis.
“Most studies reported improvements in pain and sleep quality,” states the review, which found that evidence of cannabinoid effectiveness was “strongest for fibromyalgia.”
Fibromyalgia is a chronic condition characterized by widespread musculoskeletal pain, fatigue and sleep disturbances. The findings suggest cannabinoids may offer symptomatic relief for some patients, although the strength of the evidence varied considerably depending on the condition and treatment being evaluated.
The review also found generally favorable safety outcomes across the research examined. “Globally, cannabinoids were well tolerated,” the researchers wrote.
For rheumatoid arthritis and osteoarthritis, researchers found considerably less evidence supporting cannabinoid treatment, reflecting the relatively small number of available studies and inconsistencies in their findings.
Despite the encouraging results reported in many studies, the review acknowledged that the “findings are inconsistent,” with limitations including small sample sizes, differences in cannabinoid formulations and potential sources of bias.
Researchers also noted that optimal dosing, THC-to-CBD ratios and methods of administration have not been firmly established, and that additional studies are needed to better understand long-term effectiveness and safety.
The review concluded that cannabinoid-based therapies may provide short-term benefits for some patients, particularly those with fibromyalgia, but that current evidence remains insufficient to support routine clinical recommendations for rheumatic diseases. Larger randomized trials and longer-term research could help determine which patients are most likely to benefit and what treatment approaches are most effective.










